title: Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy.
abstract: Lung cancer has the highest morbidity and mortality of any malignant tumor. To improve efficacy and reduce toxicity in patients with advanced non-small cell lung cancer (NSCLC), it is important to integrate traditional and conventional medicine. Two hundred and forty patients with advanced NSCLC were randomized to tetrandrine plus GP or GP only. We infused gemcitabine on days 1 and 8; cisplatin on day 1. The tetrandrine group received continuous i.v. infusion for 10 days, with treatment repeated every 21 days. After 2 consecutive treatment cycles, we used RECIST criteria to evaluate short-term efficacy. Quality of life (QOL) was assessed according to Karnofsky score (KPS) and body weight change. We used NCI CTC 3.0 to evaluate treatment toxicity. The short-term objective response rate was 36.1% in the tetrandrine group and 24.3% in the controls (P=0.057). The short-term disease control rate was 63.9% in the tetrandrine group and 52.3% in the controls (P=0.081). The 1-year survival rates were 45.7% and 31.3%, respectively (P=0.059). KPS scores improved by 49.1% and 32.4%, respectively (P=0.012). Body weight increased by 28.7% in the tetrandrine group and 16.2% in the controls (P=0.027). The incidence of grade 2-4 leukopenia, thrombocytopenia, nausea, and vomiting in the tetrandrine group was 38.0%, 19.4%, 46.3%, and 16.7%, respectively; the control group figures were 53.2%, 34.2%, 63.0% and 27.9% (P<0.05). Tetrandrine may improve short-term efficacy and survival in patients with advanced NSCLC. Tetrandrine may also mitigate adverse reactions to chemotherapy and improve QOL for patients with NSCLC.
authors.affiliation: Department of Oncology, Xijing Hospital, State Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an 710032, China;
authors.forename: Wenchao
authors.initials: W
authors.lastname: Liu
authors.forename: Ju
authors.initials: J
authors.lastname: Zhang
authors.forename: Cheng
authors.initials: C
authors.lastname: Ying
authors.forename: Qianrong
authors.initials: Q
authors.lastname: Wang
authors.forename: Chen
authors.initials: C
authors.lastname: Yan
authors.forename: Yang
authors.initials: Y
authors.lastname: Jingyue
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhaocai
authors.forename: Xue
authors.initials: X
authors.lastname: Yan
authors.forename: Shi
authors.initials: S
authors.lastname: Heng-Jun
authors.forename: Jiang
authors.initials: J
authors.lastname: Lin
keywords: GP regimen; chemotherapy; non-small cell lung cancer; tetrandrine